Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
First Claim
1. A method of treating diseased skin comprising administering an antagonist molecule to a mammal with the diseased skin wherein the diseased skin is characterized by cutaneous lymphocyte antigen positive T cells and the antagonist molecule specifically binds to the polypeptide comprising the amino acid sequence as shown in SEQ ID NO:
- 2 or SEQ ID NO;
4, and whereby administration of the antagonist molecule improves, prevents, inhibits or reduces the diseased skin.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to methods of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cell. In particular, diseases or disorders including contact dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous T cell lymphoma, bullous pemphigoid, alopecia aereata, vitiligo, acne rosacea, prurigo nodularis, and herpes simplex virus, or combination thereof will benefit from the administration of an IL-31 antagonist. The invention also includes methods of predicting a therapeutically responsive patient population.
-
Citations
20 Claims
-
1. A method of treating diseased skin comprising administering an antagonist molecule to a mammal with the diseased skin wherein the diseased skin is characterized by cutaneous lymphocyte antigen positive T cells and the antagonist molecule specifically binds to the polypeptide comprising the amino acid sequence as shown in SEQ ID NO:
- 2 or SEQ ID NO;
4, and whereby administration of the antagonist molecule improves, prevents, inhibits or reduces the diseased skin. - View Dependent Claims (2, 3, 4, 5, 6)
- 2 or SEQ ID NO;
-
7. A method for treating pruritis comprising administering an antagonist molecule to a mammal with the pruritis wherein the pruritis is characterized by cutaneous lymphocyte antigen positive T cells and wherein the antagonist molecule specifically binds to the polypeptide having the amino acid sequence as shown in SEQ ID NO:
- 2 or in SEQ ID NO;
4, and whereby administration of the antagonist molecule improves, prevents, inhibits or reduces the pruritis. - View Dependent Claims (8, 9, 10, 11, 17, 18, 19, 20)
- 2 or in SEQ ID NO;
- 12. A method for predicting therapeutic response to an IL-31 antagonist in an individual in need of IL-31 antagonist therapy comprising obtaining a biological sample from the patient, isolating circulating cutaneous lymphocyte positive T cells from the biological sample, and detecting IL-31 production from the isolated cutaneous lymphocyte positive T cells.
Specification